Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum

Biol Pharm Bull. 2010;33(2):238-43. doi: 10.1248/bpb.33.238.

Abstract

Baicalein, an extract from Scutellaria baicalensis, was evaluated for its ability to inhibit the influenza virus in vivo. Oral administration of baicalein to BALB/c mice infected with the influenza A/FM1/1/47(H1N1) virus showed significant effects in preventing death, increasing the mean time to death, inhibiting lung consolidation, and reducing the lung virus titer in a dose-dependent manner. These effects are believed to be due to baicalin, the metabolite of baicalein in the serum. At a concentration of baicalin 2 microg/ml in overlay medium, it showed significant inhibition in the plaque assay, and the mean IC(50) value of baicalin was calculated as 1.2 microg/ml in the cytopathic effect assay. Our results showed that baicalein warrants further research as a potential antiinfluenza viral agent.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / blood
  • Antiviral Agents / therapeutic use*
  • Cell Line
  • Cytopathogenic Effect, Viral / drug effects
  • Dogs
  • Female
  • Flavanones / therapeutic use*
  • Flavonoids / blood*
  • Influenza A Virus, H1N1 Subtype / drug effects*
  • Influenza A Virus, H1N1 Subtype / growth & development*
  • Mice
  • Mice, Inbred BALB C
  • Orthomyxoviridae Infections / blood
  • Orthomyxoviridae Infections / drug therapy
  • Plant Extracts / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Scutellaria baicalensis
  • Viral Plaque Assay

Substances

  • Antiviral Agents
  • Flavanones
  • Flavonoids
  • Plant Extracts
  • Scutellaria baicalensis extract
  • baicalin
  • baicalein